We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+49.77%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$664M
AUM Growth
+$41.7M
Cap. Flow
-$3.02M
Cap. Flow %
-0.45%
Top 10 Hldgs %
60.97%
Holding
41
New
11
Increased
8
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$25.5M
2
IMVT icon
Immunovant
IMVT
+$14.5M
3
ACLX
Arcellx
ACLX
+$13.6M
4
ELVN icon
Enliven Therapeutics
ELVN
+$9.97M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$9.24M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$43.3M
2
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$22.3M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$20.7M
4
VRDN icon
Viridian Therapeutics
VRDN
+$15.6M
5
AKRO
Akero Therapeutics
AKRO
+$8.84M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
1
Xenon Pharmaceuticals
XENE
$6.32B
$65.4M 9.86%
1,659,111
+64,179
+4% +$2.34M
VRDN icon
2
Viridian Therapeutics
VRDN
$2.13B
$59M 8.89%
2,020,166
-676,174
-25% -$15.6M
COGT icon
3
Cogent Biosciences
COGT
$6.79B
$49.9M 7.53%
4,319,940
– –
BLU
4
DELISTED
BELLUS Health Inc.
BLU
$43.6M 6.57%
5,303,557
+175,000
+3% +$1.63M
MRUS
5
DELISTED
Merus
MRUS
$42.3M 6.37%
2,732,567
+116,805
+4% +$2.06M
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
$36M 5.42%
5,738,500
– –
ACRS icon
7
Aclaris Therapeutics
ACRS
$730M
$29.6M 4.46%
1,880,286
-530,336
-22% -$8.53M
AKRO
8
DELISTED
Akero Therapeutics
AKRO
$29.4M 4.44%
537,076
-206,396
-28% -$8.84M
NUVL
9
DELISTED
Nuvalent
NUVL
$27.2M 4.1%
+913,621
New +$25.5M
CLDX icon
10
Celldex Therapeutics
CLDX
$2.77B
$22.1M 3.33%
495,823
-42,989
-8% -$1.53M
IMVT icon
11
Immunovant
IMVT
$8.09B
$20.4M 3.08%
+1,150,505
New +$14.5M
ARWR icon
12
Arrowhead Research
ARWR
$12.1B
$18.7M 2.82%
462,111
+58,033
+14% +$1.92M
CELC icon
13
Celcuity
CELC
$4.03B
$18.6M 2.8%
1,327,952
+407,488
+44% +$4.17M
ACLX
14
DELISTED
Arcellx
ACLX
$18.3M 2.76%
+591,437
New +$13.6M
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$1.84B
$17.5M 2.64%
688,445
-49,665
-7% -$1.16M
DAWN
16
DELISTED
Day One Biopharmaceuticals
DAWN
$15.9M 2.4%
739,661
– –
RXDX
17
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$14M 2.11%
+127,156
New +$8.25M
ALLK
18
DELISTED
Allakos
ALLK
$13.8M 2.09%
1,643,500
– –
KURA icon
19
Kura Oncology
KURA
$922M
$13.6M 2.06%
1,099,407
+200,000
+22% +$2.91M
FDMT icon
20
4D Molecular Therapeutics
FDMT
$526M
$13.3M 2%
+598,385
New +$9.24M
RNAM
21
DELISTED
Avidity Biosciences
RNAM
$13.1M 1.98%
+590,705
New +$8.81M
ENTA icon
22
Enanta Pharmaceuticals
ENTA
$372M
$10.4M 1.57%
223,494
+120,000
+116% +$5.47M
ELVN icon
23
Enliven Therapeutics
ELVN
$3.78B
$10.2M 1.54%
+623,699
New +$9.97M
ALPN
24
DELISTED
Alpine Immune Sciences Inc
ALPN
$9.74M 1.47%
1,325,000
– –
ETNB
25
DELISTED
89bio
ETNB
$9.65M 1.45%
+758,244
New +$6.82M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Commodore Capital held 41 positions worth $664M, up 6.7% from $622M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Commodore Capital's Q4 2022 filing shows 11 new, 8 increased, 7 reduced and 6 closed positions. Its largest new stake was Nuvalent: 913,621 shares worth $27.2M. The largest sale was Cytokinetics, an estimated $43.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Commodore Capital's largest Q4 2022 buy was Nuvalent: 913,621 shares worth $27.2M.
  • Commodore Capital added most to Enanta Pharmaceuticals in Q4 2022, an estimated $5.47M increase.
  • Commodore Capital's biggest Q4 2022 reduction was Viridian Therapeutics, cutting an estimated $15.6M.
  • Commodore Capital fully exited Cytokinetics in Q4 2022, selling an estimated $43.3M.
  • Commodore Capital's ten largest holdings make up 61% of its $664M portfolio in Q4 2022.
  • Commodore Capital opened 11 new positions and closed 6 in Q4 2022.
  • Commodore Capital's portfolio value rose 6.7% quarter-over-quarter to $664M.

Based on Commodore Capital's 13F filing for Q4 2022, filed 14 Feb 2023.